Treatment of Fibrous Dysplasia of Bone with Gonadotropin-Independent Precocious Puberty and Frequent Vaginal Bleeding in Females
This protocol addresses female patients with fibrous dysplasia of bone who present with gonadotropin-independent precocious puberty, advanced bone age, and frequent vaginal bleeding — a specific clinical picture that calls for a targeted management approach.
Clinical Situation
- Female sex
- Gonadotropin-independent precocious puberty with autonomous sex steroid production
- Advanced bone age
- Frequent vaginal bleeding
Treatment for precocious puberty is indicated when bone age is advanced and there is frequent bleeding. This reflects gonadotropin-independent sex steroid production, which can result in precocious puberty and recurrent ovarian cysts in girls and women.
Treatment Approach — Partial Overview
In this setting, monitoring for the development of central puberty is an important part of management, and the addition of a gonadotropin-releasing hormone analogue may be indicated depending on clinical progression. The complete regimen — including specific agent criteria, sequencing, and monitoring parameters — is detailed in the full protocol.
Full algorithm, agent selection, and clinical decision criteria are available in the structured evidence-based protocol.
References
DOI: 10.1186/s13023-019-1102-9
- Treatment for precocious puberty is indicated if bone age is advanced and there is frequent bleeding.
- Gonadotropin-independent sex steroid production resulting in precocious puberty, recurrent ovarian cysts in girls and women or autonomous testosterone production in boys and men.
- Patients should be monitored for central puberty and the need to add a gonadotropin-releasing hormone analogue (GnRHa), e.g. leuprolide.
View source ↗